# Post Market Clinical Follow-up Study for the Amvia/Solvia Pacemaker Family

Study · id `cardio:ct-nct06018818` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06018818](<https://clinicaltrials.gov/study/NCT06018818>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06018818

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems; Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

## Technical summary

Registry record NCT06018818. Allocation not applicable; no masking; primary purpose treatment. Start 2023-08-23 (actual); primary completion 2025-07-21 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 129 participants (enrolled count; ClinicalTrials.gov record NCT06018818, source copy `cardio:ctgov-nct06018818-2025-08-24`, retrieved 2026-10-26)
- Started: 2023-08-23 (actual) (ClinicalTrials.gov record NCT06018818, source copy `cardio:ctgov-nct06018818-2025-08-24`, retrieved 2026-10-26)
- Primary completion: 2025-07-21 (actual) (ClinicalTrials.gov record NCT06018818, source copy `cardio:ctgov-nct06018818-2025-08-24`, retrieved 2026-10-26)
- Completion: 2025-07-21 (actual) (ClinicalTrials.gov record NCT06018818, source copy `cardio:ctgov-nct06018818-2025-08-24`, retrieved 2026-10-26)
- Countries: Austria; Germany (ClinicalTrials.gov record NCT06018818, source copy `cardio:ctgov-nct06018818-2025-08-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06018818-2025-08-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Post Market Clinical Follow-up Study for the Amvia/Solvia Pacemaker Family
- Condition: Bradycardia
- Condition: Heart Failure
- Intervention (Device): Amvia/Solvia pacemaker family
- Lead sponsor: Biotronik SE & Co. KG
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Bradycardia (`cardio:bradycardia`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Biotronik SE & Co. KG (`cardio:org-biotronik-se-co-kg`)

## Provenance

Content hash: a53dae63942eadfdb4ef9b9a5dc69b90dd907d18051fc20000b56df277e573b7
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
